WilmerHale Advises Underwriters in Follow-On Public Offering of Amylyx Pharmaceuticals
WilmerHale represented the underwriters in the follow-on public offering of 7,697,812 shares of common stock of Amylyx Pharmaceuticals, Inc., a biopharmaceutical company founded with the goal of improving the quality and length of life for patients suffering from neurodegenerative diseases. The shares of common stock were issued at a public offering price of $32.00 per share. The gross proceeds to Amylyx were $246.3 million before deducting underwriting discounts, commissions, and offering expenses. The offering priced on October 6, 2022 and closed on October 11, 2022. The team consisted of
Lisa Firenze,
Jeffries Oliver-Li,
Ryan Brewer, and
Molly Nelson, with assistance from
Stuart Falber,
Bruce Manheim,
Colleen Superko, and
Heidi Treiber.
